GlassScriptPhysician profile
Alex T Meiser
NPI 1962054585
$12,138.31
in general payments reported to CMS, 2019-2025
29 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,726 · 2022: $2,037 · 2023: $3,227 · 2024: $3,900 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,415 · Consulting Fee: $2,495 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,415.26 |
| Consulting Fee | $2,495.00 |
| Education | $465.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,895.99 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Abbvie INC. | $1,390.31 | 2021-2025 | |
| Incyte Corporation | $1,354.38 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $1,342.23 | 2021-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $869.89 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $773.05 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $616.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $601.35 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $444.77 | 2021-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $423.27 | 2021-2025 | Aklief, Oracea, Epsolay |
| Ucb, INC. | $420.31 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $352.04 | 2023-2025 | Zoryve |
| Genzyme Corporation | $327.61 | 2022-2025 | |
| Dermavant Sciences, INC. | $284.67 | 2022-2024 | Vtama |
| Leo Pharma INC. | $254.69 | 2021-2025 | Adbry, Anzupgo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $163.41 | 2022-2025 | |
| Amgen INC. | $102.92 | 2021-2025 | Otezla, Otezla |
| Nobelpharma America, LLC | $101.50 | 2023 | |
| Organon LLC | $94.65 | 2025 | Vtama |
| Epi Health, LLC | $70.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.89 | 2022-2023 | Spevigo |
| Mayne Pharma Commercial LLC | $55.02 | 2024 | |
| Almirall LLC | $51.06 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $17.26 | 2023 | Ycanth |
| Paratek Pharmaceuticals, INC. | $16.05 | 2022 | |
| Journey Medical Corporation | $16.00 | 2022 | |
| Kyowa Kirin, INC. | $15.07 | 2023 | Poteligeo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Helsinn Therapeutics (U.S.), INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Meiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.